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Abstract
Background: Mutations in the progranulin (PGRN) gene, leading to haploinsufficiency, cause familial frontotemporal lobar
degeneration (FTLD-TDP), although the pathogenic mechanism of PGRN deficit is largely unknown. Allelic loss of PGRN was
previously shown to increase the activity of cyclin-dependent kinase (CDK) CDK6/pRb pathway in lymphoblasts expressing
the c.709-1G.A PGRN mutation. Since members of the CDK family appear to play a role in neurodegenerative disorders and
in apoptotic death of neurons subjected to various insults, we investigated the role of CDK6/pRb in cell survival/death
mechanisms following serum deprivation.
Methodology/Principal Findings: We performed a comparative study of cell viability after serum withdrawal of established
lymphoblastoid cell lines from control and carriers of c.709-1G.A PGRN mutation, asymptomatic and FTLD-TDP diagnosed
individuals. Our results suggest that the CDK6/pRb pathway is enhanced in the c.709-1G.A bearing lymphoblasts.
Apparently, this feature allows PGRN-deficient cells to escape from serum withdrawal-induced apoptosis by decreasing the
activity of executive caspases and lowering the dissipation of mitochondrial membrane potential and the release of
cytochrome c from the mitochondria. Inhibitors of CDK6 expression levels like sodium butyrate or the CDK6 activity such as
PD332991 were able to restore the vulnerability of lymphoblasts from FTLD-TDP patients to trophic factor withdrawal.
Conclusion/Significance: The use of PGRN-deficient lymphoblasts from FTLD-TDP patients may be a useful model to
investigate cell biochemical aspects of this disease. It is suggested that CDK6 could be potentially a therapeutic target for
the treatment of the FTLD-TDP.
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Introduction
Frontotemporal Lobar Degeneration (FTLD) is the second most
common form of cortical dementia in the presenium, accounting
for approximately 20% of dementia patients in this age group. In
one of the most common forms of FTLD, there are deposits in the
affected regions of ubiquitin-immunoreactive bodies containing
mainly TDP-43 protein, and thus named FTLD-TDP [1]. FTLD-
TDP is characterized by a widespread atrophy largely affecting the
frontal, temporal, and parietal lobes with neuronal loss, reactive
atrocytosis, and TDP-43 immunoreactive lesions [2]. The latter
include neuronal cytoplasmic inclusions (NCI), less frequent
oligodendroglial inclusions (GI), neuronal intranuclear inclusions
(NII), and dystrophic neurites (DN). Various subtypes of FTLD-
TDP have been proposed based on the proportion and
distribution of the TDP-43 immunoreactive lesions [3,4]. A large
subset of FTLD-TDP patients has been identified to harbor loss-
of-function mutations (including null mutations) in the gene
encoding progranulin (PGRN) [5,6], and a smaller number of
mutations in the valosin-containing protein (VCP) gene [7].
The relationship between PGRN deficiency and FTLD is
largely unknown. PGRN is a 593 amino acid, 86 kDa cysteine-
rich protein containing a signal peptide and 7.5 repeats of highly
conserved granulin motifs [8]. PGRN is widely distributed [8],
including the central nervous system (CNS) [4,5]. Previous
research has suggested that PGRN may function as an autocrine
neuronal growth factor involved in the inflammatory neuronal
repair process in the CNS [9]. Recently, the finding that PGRN
binds to the tumor necrosis factor receptor (TNFR) has provided
a plausible mechanism to explain the anti-inflammatory action of
PGRN [10].
PGRN has been reported to promote neuronal survival in
culture [11], though the degree of this effect is controversial [12].
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Conversely, PGRN-deficient neurons display reduced survival (but
only in stressful conditions, e.g. following H2O2 administration)
[13]. Studies utilizing non-neuronal cells suggest that PGRN can
influence apoptosis [13–16].
We previously described a prevalent ancestral c.709-1G.A
mutation related to Basque population [17,18]. The c.709-1G.A
mutation results in null allele, as most of the pathogenic mutations
described up to now, suggesting that FTLD in these families results
from PGRN haploinsufficiency [5]. In a recent report from this
laboratory, we described alterations in cell cycle-related proteins in
lymphoblastoid cell lines derived from peripheral blood mono-
nuclear cells (PBMCs) of c.709-1G.A carriers. In particular, we
detected enhanced levels and activity of CDK6 [19] associated
with increased cell proliferation. These cell cycle disturbances were
considered as systemic manifestations of the proposed aberrant cell
cycle activation in neurodegenerative disorders including FTD
[20,21]. On the other hand, there is a growing evidence for the
involvement of cell cycle CDKs in neurodegenerative disorders
and neuronal apoptosis [21–23]. Induction of CDKs occurs in
vivo in mature adult neurons during focal stroke and kainate-
induced excitotoxicity [24,25]. It is also seen in neuronal cultures
deprived of trophic factors or treated with DNA damaging agents
[23]. On these grounds, we found interesting to study the influence
of PGRN deficiency on the CDK/pRb pathway and cell survival
under conditions of serum deprivation. It is well known that
a functional trophic factor deficiency in the microenviroment of
vulnerable neurons plays a role in the etiopathogeny of
neurodegenerative diseases [26,27].
Increasing evidences have suggested that subsets of bio-
chemical dysfunctions affecting the brain of neurodegenerative
diseases patients may also be traced outside the CNS [28].
Therefore peripheral cells, such as fibroblasts or blood
lymphocytes have been extensively used in search for useful
biomarkers that may correlate with expression and/or pro-
gression of the relative disease [29–31]. We demonstrated
previously the usefulness of Epstein Barr Virus (EBV)-immor-
talized lymphocytes to study cell survival/death mechanisms in
AD [32–35]. Since cellular response is not affected by the viral
transformation [32–36], the lymphoblastoid cell lines resulting
from the EBV transformation represent an easy form to obtain
unlimited material to study regulatory mechanisms associated to
neurodegeneration. In this work, we carried out a comparative
analysis of vulnerability to different noxious stimuli in immor-
talized lymphocytes from control subjects and individuals
carrying the PGRN mutation c.709-1G.A, asymptomatic or
suffering from FTLD-TDP. Here, we report an increased
resistance to serum withdrawal-induced apoptosis in non-
neuronal cells carrying the c.709-1G.A PGRN mutation linked
to FTLD-TDP. The protective mechanism involves increased
CDK6 activity and it is accompanied by decreased caspase
activation and lower dissipation of mitochondrial membrane
potential. CDK6 inhibitors sensitize PGRN mutation positive
cells to serum withdrawal-induced apoptosis. It is suggested that
CDK6 can be a therapeutic target for FTLD-TDP patients.
Results
Cellular Response to Stress in Control and c.709-1G.A
PGRN Carriers Lymphoblasts
We first studied the cellular response to various insults
previously known to cause cell death, such as H2O2, 2-deoxy-D-
ribose (2dRib) [44,45] or serum deprivation, in lymphoblasts from
control and c.709-1G.A carriers. As shown in Table 1, the
oxidative noxae, H2O2 or 2dRib induced cell death in control and
PGRN deficient cells. A trend towards more resistance to cell
death was observed in PGRN deficient cells although there was no
statistically significance. In contrast, lymphoblasts carrying the
PGRN mutation appear to be resistant to cell death induced by
serum withdrawal.
The serum dependence of cell survival for control or PGRN
deficient lymphoblasts is shown in Fig. 1A. As expected, the cell
number was significantly higher in cultures of c.709-1G.A
carriers in the presence of progressively decreasing serum
concentrations. This observation is in consonance with previous
work demonstrating enhanced proliferative activity in lympho-
blasts carrying the PGRN mutation c.7091-G.A [19]. Following
72 h of serum deprivation, the number of cells in control cultures
was below the initial seeding while the number of PGRN deficient
lymphoblasts did not change. No differences were observed in the
proliferative activity (as assessed by BdU incorporation) of control
and c.709-1G.A carriers cells under serum replacement (Fig. 1B),
thus ruling out that enhanced proliferation could mask the
resistance of PGRN deficient cells to serum deprivation-induced
death. Data in Fig. 1C summarizes the kinetics of the cellular
response to serum deprivation of all cell lines used in this study,
derived from carriers of the c.709-1G.A PGRN mutation,
asymptomatic and FTLD affected cases, and control individuals.
In control cultures, near 30% of cells died after 3-day period of
serum starvation, whereas less than 10% of PGRN mutated cells
died during the same period of time. It is noteworthy that there
was no differences in survival between cells from asymptomatic or
patients.
Serum Withdrawal Induces Apoptosis
Because cell death can occur via apoptosis or necrosis, it was
important to determine which mechanism was involved in serum-
starved cells. Apoptosis is characterized by a number of
morphological and biochemical events that distinguish it from
necrosis. Serum withdrawal-induced cell death was therefore
assessed by different procedures. These include 1) flow cytometric
analysis of cellular DNA content, 2) microscopic examination of
nuclei stained with DAPI, 3) dependence of caspase activity, 4)
flow cytometric analysis of mitochondrial membrane potential
following serum deprivation, 5) flow cytometric analysis of
executive caspases activity by using the Vybrant FAM Caspase-3
and 7 kit (Invitrogen), and 6) assessment of cytochrome c release
from the mitochondria. Fig. 2A shows the cell cycle status before
and after serum deprivation in control and c.709-1G.A PGRN
mutation bearing lymphoblasts. It is shown a higher accumulation
Table 1. Cellular response to stress in control and c.709-
1G.A PGRN carriers lymphoblasts.
Condition % of surviving Cells
Control Asymptomatic FTLD Patients
H2O2 (100 mM) 5866 6664 6764
2dRib (30 mM) 6961 6768 6664
SW 6664 9563* 9263*
Lymphoblasts from control and c.709-1G.A PGRN carriers were incubated in
serum-free RPMI medium for 72 h (SW) or with 10% FBS in the presence of H2O2
or 2 deoxy Ribose (2dRib) for 24 h. The cells were then counted by Trypan blue
dye exclusion or by the MTT methods. Results are expressed as % of the
number of cells at day 0, and are the mean6SE of four independent
experiments. Statistical difference: *p,0.05 from lymphoblasts from control
individuals.
doi:10.1371/journal.pone.0037057.t001
CDK6 Inhibitors Induce Apoptosis in FTLD Cells
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of hypodiploid nuclei, following serum withdrawal, in control
cultures than in PGRN mutated lymphoblasts. Fig. 2B shows
a representative experiment demonstrating chromatin condensa-
tion in the nucleus of PGRN mutated cells. As control of apoptosis
use was made of staurosporine.
To address whether or not the activity of caspases was essential
for the observed increase in apoptosis after serum withdrawal,
lymphoblasts from control and PGRN mutation carriers were
treated with a general caspase inhibitor (z-VAD-fmk). Fig. 3A
shows that this compound prevented apoptosis in control cells,
without affecting survival of lymphoblasts from c.709-1G.A
carriers (either asymptomatic or FTLD patients). The green
fluorescent probe FLICA, binds irreversibly to activated caspases 3
and 7, thus increasing the fluorescent signal in apoptotic cells. The
assessment of the cell distribution of FLICA fluorescent signal in
serum deprived control and PGRN mutated lymphoblasts
indicates a higher increase in the activity of executive caspases
3 and 7 in control cells as compared with cells carrying the c.709-
Figure 1. Influence of PGRN haploinsufficiency on cell response to serum stimulation or withdrawal. A: Immortalized lymphocytes from
control and c.709-1G.A carriers, FTLD patients or asymptomatic individuals were seeded at an initial density of 16106/ml and incubated in RPMI
medium with decreasing concentrations of FBS or in the absence of serum for 72 h. Cell viability was determined by trypan blue exclusion under
inverted phase-contrast microscopy. Data are the mean6SE for at least four independent experiments carried out with cell lines from different
individuals *p,0.01 significantly different from control cells. B: Proliferative response of control and PGRN deficient cells in the presence or in the
absence of serum. Lymphoblasts (5000 cells/well) were seeded in 96-well plates in the presence of 10% FBS or serum replacement (SR). After 24 h,
cells were pulsed with 10 mM BrdU for 4 h. DNA synthesis was assessed by BrdU incorporation method according to the manufacturer’s instructions.
Proliferation was expressed as absorbance of stimulated minus that of nonstimulated cultures. Each bar represents the mean6SE of three
independent experiments performed in triplicate. C: Effect of PGRN deficiency on the serum deprivation-induced cell death. Lymphoblasts from
control and c.709-1G.A carriers, FTLD patients or asymptomatic individuals were seeded as above and incubated in serum-free RPMI medium for
72 h. Cells were harvested every day thereafter and cell viability was determined by trypan blue exclusion under inverted phase-contrast microscopy.
Data shown are the mean6SE of all cell lines used in this study (see Table 2). * and +p,0.05 differences significantly different between control and
asymptomatic or FTLD patients respectively.
doi:10.1371/journal.pone.0037057.g001
Table 2. Demographic characteristics of the subjects enrolled
in the study.
Control n =10 c.709-1G.A
Asymptomatic
n=12
FTLD Patients
n =7
Age (years) 5264 5364 65.462.6
Age range (31–70) (35–72) (54–70)
Gender (Male/
Female)
5/5 6/6 6/0
PGRN level (range) 95–170 29–61 20–57
Control: individuals without sign of neurological degeneration. Key: c.709-
1G.A, progranulin mutation; FTLD, frontotemporal lobar degeneration.
doi:10.1371/journal.pone.0037057.t002
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1G.A mutation, whether they are asymptomatic or FTLD
patients (Fig. 3B).
Changes in mitochondrial membrane potential (DWm) were
determined by using the fluorescent probe JC-1. After 72 h of
serum deprivation, control and c.709-1G.A PGRN mutation
carrier cells showed certain degree of mitochondrial membrane
depolarization as indicated by a decrease in the red (H)/green (I)
JC-1 fluorescence ratio (Fig. 4A). However, there were important
differences in the extent of depolarization. After 72 h of serum
deprivation (Fig. 4B right panel) the drop in red/green fluores-
cence ratio was significantly decreased in control cells, while
PGRN deficient cells, from asymptomatic or FTLD patient, were
only slightly depolarized as expected because of the lack of cell
death detected in these conditions. No differences in membrane
potential were observed in control and PGRN mutated cells prior
to serum starvation (Fig. 4B left panel).
The release of mitochondrial cytochrome c following serum
deprivation further indicates the activation of the ‘‘intrinsic’’
(mithochondrial initiated) apoptotic pathway. Fig. 5 shows that
serum deprivation-induced release of cytochrome c to the cytosolic
compartment is enhanced in control lymphoblasts compared with
the c.709-1G.A PGRN mutation bearing cells.
Figure 2. Serum withdrawal induces apoptosis. A: Effect of serum deprivation on distribution of control and c.709-1G.A lymphoblasts in cell
cycle. The experimental conditions are identical to those described in the legend of Fig. 1. Cells were harvested before and after 72 h of serum
deprivation, fixed and analyzed by flow cytometry as described under Materials and Methods. The percentage of sub-G0/G1 hypodiploid cells is
represented below. Data shown are the mean6SE of different experiments carried out with cell lines from eight control subjects, eight asymptomatic
and seven FTLD patients, carrying the PGRN c.709-1 G.A mutation, respectively. *p,0.05 significantly different from control cells. B: Representative
photomicrograph showing the presence of chromatin condensation/fragmentation (arrows) in the nuclei of control cells following 72 h of serum
withdrawal. As a control of apoptosis, cells from non-demented individuals were treated with 1 mM staurosporine for 5 h. Nuclei were stained with
DAPI.
doi:10.1371/journal.pone.0037057.g002
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Figure 3. Serum deprivation-induced apoptosis is accompanied by changes in caspase activation. A: Influence of the pan-caspase z-
VAD-fmk inhibitor on survival of lymphoblasts derived from control, asymptomatic and FTLD patients following serum deprivation. Cells were seeded
at an initial density of 16106/ml and incubated in serum-free RPMI medium for 72 h in the absence or in the presence of 50 mM z-VAD-fmk for 72 h.
Results shown are the mean6SE of different experiments carried out with cell lines from four control subjects, asymptomatic or FTLD patients,
carrying the PGRN c.709-1G.A mutation, respectively. *p,0.05 significantly different from control cells. B: Caspase activation in serum-deprived
lymphoblasts from control and c.709-1G.A carriers. Cells were incubated as above and then labeled with the FLICA reagent, following the
manufacture’s recommendation to detect its binding to active caspases 3 and 7. A representative flow cytometric analysis of the frequency
distribution of cells according their green fluorescence is showing. Below it is shown the percentage of cells with active caspases 3 and 7 (mean6SE)
of 3 observations carried out in different cell lines from control or c.709-1G.A PGRN mutation carriers individuals. *p,0.05 significantly different
from control cells.
doi:10.1371/journal.pone.0037057.g003
CDK6 Inhibitors Induce Apoptosis in FTLD Cells
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Role of CDK/pRb Pathway on Cell Survival
Previous work from this laboratory indicated that the c.709-
1G.A PGRN mutation carriers showed increased activity and
levels of CDK6 protein under proliferating conditions [19]. We
were interested in evaluating the role of the CDK6/pRb
pathway in the survival/death of these cell lines under serum
deprivation conditions. First, we determined by quantitative
RT-PCR the expression levels of mRNA CDK6 and, by
Western blot analysis, the levels of CDK6 and pRb in control
and PGRN mutated cells following serum withdrawal. Fig. 6A,
shows that both the mRNA levels of CDK6 and protein content
increased in PGRN mutated cells incubated in the absence of
serum. Taken together our results suggest that increased
expression of CDK6 is a distinct feature of PGRN deficient
lymphoblasts independent of the presence or absence of serum.
CDK6 activity, assessed by pRb and p130 phosphorylation
status was increased in c.709-1G.A PGRN mutation carrying
cells, either asymptomatic or FLTD patients (Fig. 6B). No
differences were found in the levels of cyclins D1, D2 and D3
or in the CDK inhibitors p16 and p18 between control and
PGRN-deficient lymphoblasts (Fig. 6C).
We next inhibited CDK6 activity with an inhibitor of histone
deacetylases (HDAC) to blunt the CDK6 mRNA expression, such
as sodium butyrate (SB). Incubation of cells with SB induced
down-regulation of CDK6 mRNA, reduced protein levels and the
phosphorylation status of pRb (Fig. 7A,B) and sensitized PGRN
mutated cells to serum deprivation-induced cell death (Fig. 7C).
Cell survival of control cells was not affected by this dose of SB
(10 mM). This dose of SB was proven to be effective in blunting the
enhanced proliferative response of PGRN deficient lymphoblasts
[19]. On the other hand, we specifically inhibited CDK6 activity
with the small molecule PD332991 (Pfizer). We observed that
increasing concentrations of this compound (0.5 to 2.5 mM)
induced cell death of control and PGRN deficient lymphoblasts in
a dose-dependent manner (data not shown). Maximal effects were
observed at 1 mM PD332991. Treatment of control and PGRN
Figure 4. Mitochondrial membrane potential in lymphoblasts from control and c.709-1G.A carrier individuals. A: Lymphoblasts from
control and c.709-1G.A carriers (asymptomatic and patients) were labeled with the probe JC-1 following manufacturer’s directions before and 72 h
after serum withdrawal. Representative flow cytometric analysis of the frequency distribution of cells according their red or green fluorescence,
corresponding to the aggregated or monomeric form of the JC-1 probe is presented. B: The ratio aggregated/monomeric (H/I) form of the JC-1 probe
was determined before (left panel) and after 72 hours of serum deprivation (right panel). Values shown are the mean6SE of seven observations
carried out in different cell lines from control, asymptomatic or FTLD patients. *p,0.05 significantly different from control cells.
doi:10.1371/journal.pone.0037057.g004
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mutated cells with this dose of PD332991, induced dephosphor-
ylation of pRb protein without changes in the CDK6 mRNA and
protein levels in control and PGRN deficient cells (Fig. 7 D y E).
This treatment sensitized c.709-1G.A PGRN mutation carrier
cells to serum deprivation-induced apoptosis and increased death
of control lymphoblasts (Fig. 7F).
Role of PGRN Haploinsufficiency on the Survival of
Immortalized Lymphocytes
To further understand the influence of PGRN deficiency on cell
survival, we added recombinant PGRN in the presence or in the
absence of CDK6 inhibitors, to the culture medium. Fig. 8 shows
that exogenous PGRN mimicked the proapoptotic effects of SB,
while cooperated with PD332991 to produce a greater inhibition
of phosphorylation of pRb protein and cell survival in PGRN
deficient cells. While PGRN or SB did not affect either
phosphorylation of pRb or survival of control cells, inhibiting
CDK6 activity by PD332991, alone or in combination of PGRN,
greatly decreased the phosphorylation of pRb and consequently
raised the vulnerability of control cells to serum deprivation.
Taken together these results suggest that exogenous PGRN
blunted the enhanced CDK6 mRNA expression levels in PGRN
deficient cells. Interestingly, the treatment of PGRN deficient cells
with exogenous PGRN in the presence of serum had similar effects
than SB in preventing the increased proliferative response of these
cell lines. Moreover exogenous PGRN and PD332991 showed also
additive effects in decreasing cell proliferation (results not shown).
These observations highlight the important role of CDK6/pRb
pathway in determining the cell fate, survival/death depending on
growth factors availability.
Discussion
Results presented herein indicate that immortalized lympho-
cytes from c.709-1G.A PGRN mutation carriers, asymptomatic
or FLTD patients are more resistant to cell death induced by
serum deprivation than those derived from control individuals.
These cell lines were previously found to show enhanced
proliferative activity upon serum stimulation [19]. These neo-
plastic-like features of PGRN deficient lymphoblasts may be
Figure 5. Enhanced release of cytochrome c to the cytosol in serum-deprived lymphoblasts bearing the c.709-1G.A PGRN
mutation. A: Lymphoblasts from control and c.709-1G.A carriers were serum deprived for 72 h. Cell lysates were fractionated to isolate cytoplasmic
and crude mitochondria. The presence of cytochrome c in cytosolic and mitochondrial fractions was assessed by WB analysis using the ApoTrack
antibody cocktail, which demonstrates the purity of the fractions and loading. A representative blot of three independent experiments is shown. B:
Cytochorme c detection in cytosolic extracts from control and PGRN deficient lymphoblasts. A representative immunoblot showing cytosolic
cytochorme c in two different individuals for each condition is shown (left panel). Densitometric analysis is presented in the right panel. The data
represent the mean6SE of the cytosolic cytochrome c for four observations in different cell lines. *p,0.05 significantly different from control cells.
doi:10.1371/journal.pone.0037057.g005
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systemic manifestations of cell cycle-related events associated with
neurodegeneration, as described in several diseases of the Central
Nervous System (CNS) [46–49]. We and others reported pre-
viously a selective impairment of mechanisms involved in cell
death in peripheral cells from Alzheimer’s disease patients [32,50–
52]. Moreover, we demonstrated that the immortalization pro-
cedure did not alter the cellular response of fresh obtained
lymphocytes, to addition or withdrawal of mitogenic factors
[32,36], thus providing support for considering lymphoblastoid
cell lines as suitable model to study cell survival/death mechanisms
regulation associated with neurodegeneration and for testing novel
modifying-disease therapies.
Cell death induced by serum deprivation showed characteristics
of apoptosis. The lower sensitivity of PGRN deficient cells to
trophic factors withdrawal was accompanied by lower dissipation
of DWm, decreased activation of capases 3 and 7, and reduced
cytochrome c release from the mitochondria, compared with
control cells.
c.709-1G.A PGRN mutated cells treated with inhibitors of
CDK6 activity undergo significant apoptosis in the absence of
serum in the culture medium as they do control cells, suggesting
a role of the CDK/pRb signaling pathway in protecting PGRN
deficient cells from apoptosis. The effects of SB and PD332991 on
survival of lymphoblasts bearing the PGRN mutation are in line
with the reported effects of PD332991 on myeloma cells inhibiting
cell cycle progression and increasing the cell sensitivity to
bortezomib-induced apoptosis [53]. Considering that CDK6
inhibitors are already being used for treatment of a number of
human tumors [54] with a good tolerance, it is plausible that they
may serve as novel therapeutic drugs for FTLD.
The observed enhanced CDK/pRb activity of PGRN deficient
lymphoblasts contrasts with the fact that increased CDK activity
Figure 6. CDK6 mRNA, protein levels and pRb phosphorylation in lymphoblasts from control and c.709-1G.A carriers individuals.
Immortalized lymphocytes from control and c.709-1G.A carriers, FTLD patients or asymptomatic individuals were seeded at an initial density of
16106/ml and incubated in serum-free RPMI medium. 48 hours later cells were harvested to isolate RNA and to prepare cell lysates. A: CDK6 mRNA
expression levels were analyzed by quantitative RT-PCR (left panel), and the CDK6 protein content was analyzed by WB (right panel). The inmunoblot
shows two different cell extracts from control, asymptomatic and FTLD patients is shown. The data represent the mean6SE for six observations in
different cell lines. *p,0.05 significantly different from control cells. B: Representative inmunoblots showing pRb and p130 phosphorylation status in
two different control, asymptomatic or FTLD individuals is shown. pp = the hyperphosphorylated form of the pRb or the p130 protein. Below it is
shown the densitometric analysis of the hyperphosphorylated form of pRb and p130. Data represent the mean6SE for six independent observations
in different cell lines. C: Representative immunoblots showing the cellular content of Cyclin D1, D2 and D3, and the CDK inhibitors p16 y p18 in two
different control, asymptomatic or FTLD individuals.
doi:10.1371/journal.pone.0037057.g006
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and pRb phosphorylation have been linked to neuronal death in
a number of cell and animal models of neurodegeneration [55,56].
However, one has to take into account that alteration of cell cycle-
related events in brain and lymphocytes have different con-
sequences. Lymphocytes from PGRN mutation carrier individuals
show and enhanced proliferative activity [19] and increased
resistance to serum deprivation-induced cell death than cells
derived from control individuals. On the other hand, cell cycle
disturbances in already adult neurons results in cellular dysfunc-
tion, premature cell death, and thus neurodegeneration [57]. It is
worth mentioning that CDK6 inhibitors addition to PGRN
mutated lymphoblasts were able to restore the ‘‘normal’’ cell
response to serum stimulation [19] or withdrawal (this manu-
script), by blunting the enhanced proliferative activity or
sensitizing cells to apoptosis in the absence of serum. In both
situations, CDK6 inhibitors decreased the levels of phosphoryla-
tion of pRb protein in c.709-1G.A carrier cells to reach those of
control cells. It remains to be demonstrated whether CDK6
inhibitors would protect neurons in FTLD brain from apoptosis by
modulating the CDK6/pRb pathway, but it has been suggested
that SB and other HDAC inhibitors behave as neuroprotective
drugs [58]. These compounds prolonged the life span of cultured
cortical neurons [59] and promoted neuronal growth. Work
carried out in vivo demonstrated that they protected neurons from
ischemic stroke [60]. A neuroprotective effect of these drugs has
also been reported in animal models of neurodegenerative
disorders [61,62].
The proapoptotic effect of SB in PGRN mutated cells appears
to be directly related to PGRN insufficiency since it was mimicked
by the addition of recombinant PGRN. The fact that exogenous
PGRN mimicked the SB effects but cooperate with the inhibitor of
CDK6 activity PD332991 on cell survival, points out to the
Figure 7. Effects of sodium butyrate and PD332991 on CDK6 mRNA and protein levels and in the survival of control and c.709-
1G.A carriers lymphoblasts. Lymphoblasts were incubated as in the legend of Fig. 6 in the absence or in the presence of 10 mM SB (A, B and C)
or 1 mM PD332991 (E, F and G) for 48 h. CDK6 mRNA analysis was performed by quantitative RT-PCR, protein levels were assessed by WB. Cell survival
was determined by trypan blue exclusion under inverted phase-contrast microscopy. Values shown are the mean6SE for four independent
observations carried out in different cell lines. *p,0.05 significantly different from control cells. **p,0.05 significantly different from untreated cells.
doi:10.1371/journal.pone.0037057.g007
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alteration of CDK6 transcription as the major cause of aberrant
cell survival/death response of PGRN deficient cells.
The expression of CDK6 is negatively regulated by TDP-43
[63]. The control of CDK6 expression mediated by TDP-43
involves GT repeats in the target gene sequence. Several reports
indicate that PGRN deficiency induced mislocalization of TDP-43
protein leading to a loss of the DNA-RNA binding function of the
protein [64,65]. Indeed an increase in the cytosolic content of
TDP-43 protein could be observed in c.709-1G.A bearing
lymphoblasts, associated with increased levels of CDK6 [19]. It
appears therefore that altered DNA/RNA binding protein
function, rather than toxic aggregation is central to TDP-43-
related neurodegeneration. Two recent reports support this
asseveration, the first one indicates that there is no correlation
between protein aggregates formation and severity of the disease
[66] while the second suggests that TDP-43 function is required
for cell survival in ALS [67].
Our results show no differences in the cellular response to serum
deprivation and content of CDK6 among lymphoblasts derived
from c.709-1G.A mutation carriers, asymptomatic or presenting
already clinical signs of dementia. Since most of the asymptomatic
carriers are younger than the patients, this finding suggests that
dysfunction of cell survival could be an early manifestation of the
disease. Nonetheless, there are c.709-1G.A carriers that remain
asymptomatic until advanced age suggesting that the altered cell
survival/death response is not sufficient to cause the disease and
there must be other genetic or environmental factors in de-
termining the onset of clinical disease.
The reason for the distinct vulnerability to serum deprivation
of PGRN deficient cells cannot be ascertained with the present
data. However, the possibility should be considered that changes
in signaling molecules and/or receptors might be altered. On
these grounds, it is worth to mention that it has been recently
reported disturbances in circulating levels of several cytokines in
Figure 8. Effects of exogenous progranulin in the serum deprivation-induced cell death. Lymphoblasts from control or c.709-1G.A
carriers individuals were incubated in serum-free RPMI medium in the absence or in the presence of recombinant PGRN (100 ng/ml), alone or in
combination with 10 mM SB or 1 mM PD332991. Cell survival was determined after 72 hours of serum deprivation. Data shown are the mean6SE of
four determinations carried out with different cell lines. *p,0.05 significantly different from control cells. **p,0.05 significantly different from
untreated cells. +p,0.05 significantly different from cells treated with PGRN alone. Below it is shown representative immunoblots showing the effects
of these drugs, alone or in combination of exogenous progranulin on CDK6 and pRb proteins levels.
doi:10.1371/journal.pone.0037057.g008
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the serum of asymptomatic and FLTD patients carriers of loss-
of-function PGRN mutations [68]. On the other hand, a recent
functional genomic study had revealed changes in Wnt signaling
pathway in PGRN deficient cells and demonstrated upregula-
tion of the FZD2 receptor in PGRN knockdown mice [69]. It
was suggested FZD2 could play a potentially neuroprotective
role in PGRN deficient cells. Moreover, TNF receptor has been
identified as a PGRN binding receptor [10]. Therefore,
progranulin haploinsufficiency could eventually potentiate
TNF-a signaling. Whether similar mechanisms operate in
lymphocytes from carriers of c.709-1G.A PGRN mutation is
currently under investigation in our laboratory.
Finally, an issue that needs to be taken into account for
discussion purposes is that although FTLD associated changes
detected in peripheral cells might not fully reflect those in FTLD
brain, it is evident that besides neuronal damage there are also
peripheral aspects of the disease. A close relationship seems to exist
between the state of the immune system, and particularly
lymphocytes, and some psychiatry disorders including AD [70].
As far as we know, clinical disturbances in the immune system
have not been reported in FTLD. However it is possible that some
factors, including neuroinflammatory cytokines that link the
peripheral immune and nervous systems can influence neuronal
survival in FTLD.
In summary, we provide evidence that CDK6/pRb signaling
pathway is enhanced in PGRN deficient cells, associated with
altered cell vulnerability to trophic factor deprivation. Exogenous
PGRN and inhibitors of CDK6 activity were able to restore the
normal cell response. It is suggested that the inhibition of CDK6
activity or alternatively the modulation of PGRN levels may have
a beneficial effect on FTLD-TDP. Taken together our results with
the recent findings that alkalinizing drugs [71] or the FDA-
approved HDAC inhibitor, suberoylanilide hydroxamic acid
(SAHA) are able to increase PGRN levels [72], it is possible to
envision new promising avenues for therapeutic intervention in
FLTD-TPD.
Materials and Methods
Materials
All components for cell culture were obtained from Invitrogen
(Barcelona, Spain). The kinase inhibitor PD332991 was kindly
provided by Pfizer. The inhibitor of histone deacetylases sodium
butyrate (SB), 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium
bromide (MTT), 2-Deoxy-D-ribose (2dRib) and H2O2 were
obtained from Sigma-Aldrich. The caspase inhibitor benzyloxy-
carbonyl-Val-Asp-fluoromethylketone (z-VAD-fmk) was obtained
from Calbiochem (Darmstad, Germany) and 4,6-diamino-2-
phenylindole (DAPI) was obtained from Serva (Heidelberg,
Germany). Progranulin (human) (recombinant) was obtained from
Enzo (Life Sciences). Poly (vinylidene) fluoride (PVDF) membranes
for western blots were purchased from Bio-Rad (Richmond, CA).
Antibodies against human Cdk6, pRb, p130, p16, p18 were
obtained from Santa Cruz Biotechnologies (Santa Cruz, CA).
Antibodies against Cyclin D1, D2 and D3 were obtained from Cell
Signaling, antibody against Lamin-B1 was obtained from
Calbiochem (Darmstad, Germany) and antibody against b-actin
was obtained from Sigma-Aldrich. ApoTrackTMcytochrome c
Apoptotic WB antibody cocktail (ab110415) was obtained for
MitoSciences (Eugene, Oregon, US). The enhanced chemilumi-
niscence (ECL) system was from Amersham (Uppsala, Sweden.).
Other reagents were of molecular biology grade.
Study Samples and Cell Lines
A total of 29 individual were enrolled in this study. We
studied 19 individuals with a single pathogenic splicing mutation
in the PGRN gene (c.709-1G.A), 7 of them patients of FTLD-
TDP, 12 asymptomatic and 10 control individuals without
mutation in PGRN nor any sign of neurological degeneration.
All patients were of Basque descent. Asymptomatic and control
individuals were relatives of patients. All patients were di-
agnosed as FTD in the Donostia Hospital by applying
consensus criteria as published elsewhere [37]. Patients exhibited
variable phenotype initial symptoms. Four of them presented
the behavioral variant of frontotemporal dementia (bv-FTD),
one progressive nonfluent aphasia, and corticobasal basal
syndrome (CBS), the other patients developed a relatively
rapidly progressive dementia with features that led to a second-
ary diagnosis. Notably, this secondary diagnosis was CBS in
three of the bv-FTD cases. It is shown that PGRN levels in
plasma were strongly reduced in affected and unaffected
subjects carrying the c.709-1G.A mutation. Table 2 sum-
marizes the demographic characteristics and the plasma levels of
PGRN of all subjects enrolled in this study.
All study protocols were approved by the Donostia Hospital and
the Spanish Council of Higher Research Institutional Review
Board and are in accordance with National and European Union
Guidelines. In all cases, peripheral blood samples were taken after
written informed consent of the patients or their relatives to
determine the presence of the c.709-1G.A PGRN mutation and
to establish the lymphoblastoid cell lines.
DNA was extracted from blood cells using standard procedures.
PGRN gene sequencing procedures used at our laboratory have
been published elsewhere [17]. For determination of PGRN
plasma levels we used an ELISA kit (AdipoGene, Korea).
Establishment of lymphoblastoid cell lines was performed in our
laboratory as previously described [38], by infecting peripheral
blood lymphocytes with the Epstein Barr virus [39]. Cells were
grown in suspension in T flasks in an upright position, in
approximately 10 ml of RPMI-1640 (Gibco, BRL) medium that
contained 2 mM L-glutamine, 100 mg/ml penicillin/streptomycin
and, unless otherwise stated, 10% (v/v) fetal bovine serum (FBS)
and maintained in a humidified 5% CO2 incubator at 37uC.
Medium was routinely changed every two days.
Determination of Cell Proliferation
Cell proliferation was assessed by the 5-bromo-29-deoxyuridine
(BrdU) incorporation method using an enzyme-linked immunoas-
say kit procured from Roche (Madrid, Spain). Cells (5000 cells/
well) were seeded in 96-well microtiter plates. Four hours prior to
the end of the interval of measurement, BrdU (10 mM) was added.
The cells were fixed with precooled 70% ethanol for 30 min at –
20uC and incubated with nucleases following manufacturer’s
recommendations. Cells were then treated for 30 min at 37uC
with peroxidase-conjugated anti-BrdU antibody. Excess antibody
was removed by washing the cells three times, followed by the
addition of substrate solution. Absorbance was measured at
405 nm with a reference wavelength of 492 nm.
Cell Survival Assay
The cell suspension was mixed with a 0.4% (w/v) trypan blue
solution and the number of live cells was determined using
a hemocytometer. Cells failing to exclude the dye were considered
nonviable. In some experiments cell viability was checked by the
MTT assay [40] obtaining similar results.
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Assessment of Apoptosis and Caspase Activity
Flow cytometry was performed to determine the content of
apoptotic sub-G1 hypo-diploid cells [41]. Exponentially growing
cultures of cell lines were seeded at an initial concentration of
16106 cells/ml and cultured for 72 h in serum-deprived RPMI
medium. Then, cells were fixed in 75% ethanol for 1 h at room
temperature. Subsequent centrifugation of the samples was
followed by incubation of cells in phosphate-buffered saline
(PBS) containing 1 mg/ml RNase at room temperature for
20 min and staining with propidium iodide (PI) (25 mg/ml). Cells
were analyzed in an EPICS-XL cytofluorimeter (Coulter Cientı´-
fica, Mo´stoles, Spain). Estimates of cell cycle phase distributions
were obtained by computer analysis of DNA content distribution.
In addition, apoptosis was characterized by chromatin condensa-
tion/fragmentation, as determined by cell permeabilization
followed by DAPI staining and microscopy examination.
The activation of executive caspases was investigated using the
Vybrant FAM Caspase-3 and 7 Kit (Invitrogen) including FLICA
reagent that is retained within the cell, if bound to the active
caspase molecule. Lymphoblasts from control and carriers of
c.709-1G.A mutation were resuspended in 300 ml of RPMI
containing 10 ml of FLICA reagent and incubated in 5% CO2 at
37uC for 60 min. The cells were then washed with, and suspended
in wash buffer provided with the kit. The samples were analyzed
on the flow cytometer.
Analysis of Mitochondrial Membrane Potential
Changes in mitochondrial membrane potential (DWm) were
analyzed by means of the fluorescent dye 5,5,6,6-tetrachloro-
1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide (JC-1; Molec-
ular Probes) as reported [42]. When live cells are incubated with
JC-1, mitochondrial membrane polarization allows JC-1 to
selectively enter mitochondria, which causes the reversible
formation of JC-1 aggregates. JC-1 showed a spectral shift in
emitted light from 530 nm (emission of JC-1 monomeric form;
green) to 590 nm (emission of J-aggregate; green-orange) upon
excitation at 488 nm. After 72 hours of serum deprivation control
and PGRN deficient lymphoblasts were incubated with JC-1 at
final concentration 5 mg/ml for 15 min at 37uC, in the dark. At
the end of the incubation period, the cells were washed twice in
cold PBS, resuspended in a total volume of 500 ml, and analyzed
by flow cytometry. The ratio of red/green fluorescence intensity
was calculated before and after 72 h of serum deprivation. A
decrease in this ratio indicates mitochondrial depolarization (i.e
loss of mithocondrial membrane potential).
Immunoblotting Analysis
50–100 mg of protein from cell extracts were fractionated on
a SDS polyacrylamide gel, and transferred to PVDF membrane
(Bio-Rad). The amount of protein and the integrity of transfer
were verified by staining with Ponceau-S solution (Sigma). The
membranes were then blocked with non-fat milk and incubated,
overnight at 4uC, with primary antibodies at the following
dilutions: 1:500 anti-pRb, 1:1000 anti-CDK6, 1:500 anti-p130,
1:100 anti-cylin D1, 1:200 anti-cyclin D2, 1:500 anti-cyclin D3,
1:200 anti-p16, 1:100 anti-p18, 1:5000 anti-b-actin, and 1:1000
anti-lamin B1. The release of cytochome c from the mitochon-
dria was assessed after cell fractioning to get cytosolic and crude
mitochondrial extracts as described [43], using the Apo-
TrackTMcytochrome c antibody cocktail. Signals from the
primary antibodies were amplified using species-specific antisera
conjugated with horseradish peroxidase (Sigma) and detected
with a chemiluminiscent substrate detection system ELC
(Amersham). The specificity of the antibodies was checked by
omitting the corresponding primary antibody in the incubation
medium. The relative protein levels were determined by
scanning the bands with a GS-800 imaging densitometer
provided with the Quantity One 4.3.1 software from BioRad,
and normalized by those of b-actin.
Statistical Analysis
Unless otherwise stated, all data represent means 6 Standard
Error of the Mean (SE). Statistical analysis was performed on the
Data Desk package (version 4.0) for Macintosh. Statistical
significance was estimated by analysis of variance (ANOVA)
followed by the Fischer’s LSD test for multiple comparisons.
Differences were considered significant at a level of p,0.05.
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